Erik Alcantar-Orozco

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial

David A. Sallman, Tessa Kerre, Violaine Havelange et al. · The Lancet Haematology · 2023 · 93 citations · Full text

Medicine, Hematology, Immunology +17

Potential Limitations of the NSG Humanized Mouse as a Model System to Optimize Engineered Human T cell Therapy for Cancer

Erik Alcantar-Orozco, Hannah Gornall, Vania Baldan et al. · Human Gene Therapy Methods · 2013 · 42 citations · Full text

Life Sciences, Immunology, Oncology +17

Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC.

Hans Prenen, Jeroen Dekervel, Alain Hendlisz et al. · Journal of Clinical Oncology · 2021 · 41 citations

Life Sciences, Immunology, Oncology +17

CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo

Gray Kueberuwa, Hannah Gornall, Erik Alcantar-Orozco et al. · Journal for ImmunoTherapy of Cancer · 2017 · 25 citations · Full text

Life Sciences, Immunology, Oncology +15

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

David A. Sallman, Jason Brayer, Xavier Poiré et al. · Blood · 2019 · 25 citations · Full text

Medicine, Hematology, Oncology +17